Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized, Controlled Trial of a Novel Mobile Device Application to Improve Adherence in Children Greater Than 11 Years of Age After Cardiac Transplantation (CTOTC-10)
Brief Summary: The purpose of this study is to collect and compare information on how and when adolescent heart transplant recipients take their prescribed medication. The investigators want to find out if regular use of 'an app' on cell phones, called the Teen Pocket PATH® (TPP), can help adolescents take their medication according to their prescribed dosing schedule. This may then help reduce complications of transplant, such as rejection. The investigators also want to find out if how adolescent heart transplant recipients take their medications affects the development of antibodies in their blood. Antibodies are small proteins in the blood that may develop after heart transplantation, and which can sometimes damage a new heart.


Options:
A: Inclusion Criteria:

* Enrolled (consented) prior to hospital discharge from heart transplantation or within one month after discharge, but not later than 3 months post-transplantation;
* English as primary language or fluent in English; and
* Informed consent and assent obtained.

Exclusion Criteria:

* Positive donor-specific cytotoxicity requiring different immunosuppressive regimen from standard care;
* Inability or unwillingness of a participant to give written informed consent or comply with study protocol;
* Re-transplant or multi-organ transplant recipient;
* Condition or characteristic which in the opinion of the investigator makes the participant unlikely to complete at least one year of follow-up; or
* Current participation in other research studies that would, or might, interfere with the scientific integrity or safety of current study (e.g. by interference with immunosuppression management guidelines and study end-points).
B: Inclusion Criteria:

* a minimum of one year post renal transplant with a successful kidney graft and stable renal function (estimated glomerular filtration rate \[GFR (glomerular filtration rate)\] above 25 ml/minute per 1.73 m2).
* currently prescribed tacrolimus
* able to swallow pills
* a minimum of grade six education
* fluent in the English language.

Exclusion Criteria:

* refusal to or inability to give written informed consent.
* any visual, hearing or other sensory/motor impairments which may interfere with the testing procedures.
* have had a stroke determined to be of significant severity
* have had a head injury determined to be of significant severity
* have a current psychiatric diagnosis determined to be of significant severity
* have the presence of an acute illness (e.g., metastatic cancer), neurological disease, and other major organ failure (e.g., end stage liver disease)
C: Inclusion Criteria:

* The patient is ≥ 12 and \< 20 years of age at enrollment.
* ≥2.5 years after last liver transplantation.
* Guardian's consent, adolescent assent at enrollment.
* The patient is prescribed tacrolimus.
* The patient's MLVI (SD of tacrolimus) was \> 2 when calculated by the site for a period of 2 years prior to the review date

Exclusion Criteria:

* The patient has had transplant of an organ other than liver.
* The patient is currently listed for any organ transplantation.
* The patient is expected to transition to another service (e.g., adult clinic, another
* hospital) during the two years of the study.
* Pregnant patients.
* A temporary exclusion: the patient is not medically stable or was hospitalized for \>48 consecutive hours in the past three months.
* Site PI, study PI, or Medical Monitor determines that the patient should not be a candidate for the intervention due to factors that are not covered in the above criteria.
D: Inclusion Criteria

* Age: 18 Years to 60 Years
* Gender: both
* Patients willing and able to participate in this study
* Patients who signed the informed consent form
* Patients who can visit the center based on the study schedule in the protocol

Exclusion Criteria

* Patients who had previously received a kidney or another organ
* Patients, having positive lymphocyte cross-match
* Patients with PRA \>50%
* Patients, who underwent desensitization
* Patients, who were diagnosed with cancer in the last five years
* Patients, who themselves or their donors have positive HIV, HBsAg, or anti-HCV test results
* Patients, who were treated with other investigated drugs within 30 days from their study enrollment
* Patients, who are planning to be pregnant, or who are pregnant or breastfeeding and who are not planning to use any contraceptive method during the study period.
* Patients who were addicted to drugs/alcohol within six months of their study enrollment
* Patients, who have a mental illness that makes appropriate communication with them impossible

Answer: A